Focused On-demand Library for UMP-CMP kinase

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

PARTNER
Receptor.AI
 
UPACC
P30085

UPID:
KCY_HUMAN

ALTERNATIVE NAMES:
Deoxycytidylate kinase; Nucleoside-diphosphate kinase; Uridine monophosphate/cytidine monophosphate kinase

ALTERNATIVE UPACC:
P30085; B2R6S5; B4DPU7; E9PGI8; Q53GB7; Q5SVZ0; Q96C07; Q9UBQ8; Q9UIA2

BACKGROUND:
The enzyme UMP-CMP kinase, known for its roles as Deoxycytidylate kinase and Nucleoside-diphosphate kinase, is essential in the synthesis of new pyrimidine nucleotides. It efficiently phosphorylates pyrimidine nucleoside monophosphates at the expense of ATP, favoring UMP and CMP as substrates. Its activity extends to broad nucleoside diphosphate kinase functions, highlighting its importance in nucleotide metabolism.

THERAPEUTIC SIGNIFICANCE:
Exploring the functionalities of UMP-CMP kinase unveils potential avenues for therapeutic development. Given its integral role in nucleotide synthesis, targeting this kinase may offer novel solutions for treating metabolic abnormalities and related diseases.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.


Page 7739 of 8789